about
Nanotechnology: Future of OncotherapyOligonucleotide Therapies: The Past and the PresentHDL as a drug and nucleic acid delivery vehiclePigmy MicroRNA: surveillance cops in Therapies kingdomApproaches to Validate and Manipulate RNA Targets with Small Molecules in CellsEndogenous microRNA sponges: evidence and controversy.Delivery of DNAzyme targeting aurora kinase A to inhibit the proliferation and migration of human prostate cancer.Hematologic malignancies: newer strategies to counter the BCL-2 protein.Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2.Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapyPrognostic value of microRNA-126 and CRK expression in gastric cancer.Emerging drugs for the treatment of wound healing.HER3/ErbB3, an emerging cancer therapeutic target.Delivery strategies and potential targets for siRNA in major cancer typesIdentification of aminosulfonylarylisoxazole as microRNA-31 regulators.Natural and artificial small RNAs: a promising avenue of nucleic acid therapeutics for cancer.Prognostic value of microRNAs in gastric cancer: a meta-analysisOncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication.Microrna-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway.Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer
P2860
Q26801067-3E425602-CA2D-4C26-A2B7-761DD8453CA9Q27002403-DB7C86D0-C9C3-4B6F-AF17-7A08B92651D9Q28083209-F8D93EC3-93B8-4DFA-BAE8-29248FCA74CBQ28818470-68E52F8A-0FC7-47F6-B0F2-9DE54CD238EFQ28833658-50B85D45-1798-42E4-B800-5767BE4B5E3AQ34520689-88954293-2792-482F-9CA1-743CDF0284FEQ35794644-C81EF3CF-3E33-4027-8A6A-5623BD2C215AQ35979110-19DA676C-F334-44D8-97C0-66F85B7A433BQ36928118-6F3A3567-4526-49D7-994A-ABE16E44A66EQ37301832-7AF5B2DE-24A7-46E7-ADA0-D27B2412D077Q37344475-46F89F53-AE8F-4EF3-9826-73F33F119622Q38364058-F19723AA-A074-4A9D-A26E-7ECAE33D6385Q38615197-5B9B2A4A-73D7-48B0-908C-E1A8CB66304DQ38853191-C331F044-99D6-4F7B-832F-F0FD952A10E4Q41255588-E60CC85A-D195-45F7-AA7F-29667EB073B2Q41514193-0D2642AF-45EB-4879-9E2F-7272E7FA6632Q41548169-FFC90405-C59D-49FC-80E1-33842ED6AF3DQ41608170-C4AB1AA7-76F9-46A5-9243-453E5F478CAFQ52655127-64E4CF3B-0881-4BBD-BF79-D710893A3C37Q58767616-F12A298A-DED6-4CE4-8DB5-1C722EF3AB56
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Antisense therapeutics in oncology: current status.
@en
type
label
Antisense therapeutics in oncology: current status.
@en
prefLabel
Antisense therapeutics in oncology: current status.
@en
P2093
P2860
P356
P1476
Antisense therapeutics in oncology: current status.
@en
P2093
Ammad Ahmad Farooqi
Jordi Muntane
Zia Ur Rehman
P2860
P304
P356
10.2147/OTT.S49652
P407
P577
2014-11-03T00:00:00Z